**Schedule of Assessments**

|  | **Measures/Procedures** | **Year 1** | **Year 2** | **Year 3** | **Year 4** |
| --- | --- | --- | --- | --- | --- |
| **Month 0** | **Month 6** | **Month 12** | **Month 18** | **Month 24** | **Month 30** | **Month 36** | **Month 42** |
| Neuromed | Basic demographics  | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Vital Signs |  |  |  |  |  |  |  |  |
|  Height | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Weight | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Blood pressure  | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Anthropometry |  |  |  |  |  |  |  |  |
|  Waist circumference | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Hip circumference | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Arm circumference | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Fried Frailty Index | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Neuromedical exam |  |  |  |  |  |  |  |  |
|  Cranial nerve function | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Motor strength and tone | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Reflexes | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Sensory perception | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Coordination | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Gait | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Medication Summary  | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| ART Medication  | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| †Visual analog scale for ART adherence | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Medical comorbidities | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| COVID questionnaire | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Chronic pain questionnaire | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| TBI questionnaire: BISQ-7SF | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| †, \*CD4 Nadir  | T1, T2 |  |  |  |  |  |  |  |
| †, \*ARV history | T1, T2 |  |  |  |  |  |  |  |
| Blood draw |  |  |  |  |  |  |  |  |
|  CBC with differential | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  †T-cell enumeration | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  †HIV viral load | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Comprehensive metabolic panel | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Lipid panel | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  HgBA1c | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  PT/INR | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  C-reactive protein (HS) | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Anti-nucleocapsid SARS-CoV-2 serology | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  RPR/syphilis screen | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Hepatitis serologies | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  ‡Rapid HIV | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Urinalysis/Toxicology |  |  |  |  |  |  |  |  |
|  Amphetamines | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Barbiturates | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Benzodiazepines | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Cannabinoids | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Cocaine | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Opiates | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Phencyclidine | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Methadone | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Oxycodone | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Tricyclic antidepressants  | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Buprenorphine | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
|  Methamphetamine | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 | T1, T2 | T1 |
| Lumbar Puncture (optional) |  |  |  |  |  |  |  |  |
|  |  CSF glucose | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
|  CSF protein and albumin | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
|  CSF cell count | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
|  †CSF HIV viral load | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Neuropsych | Behavioral Notes  | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Activities of Daily Living | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Patient’s Assessment of Own Functioning (PAOFI)-6  | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| aWRAT4 Reading | T1, T2 |  |  |  |  |  |  |  |
| Trail Making Test- Part A | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Trail Making Test- Part B | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| WAIS-III Letter-Number Sequencing | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| FAS Verbal Fluency | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Hopkins Verbal Learning Test - Revised | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Animal Verbal Fluency | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Grooved Pegboard Test | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Brief Visuospatial Memory Test - Revised | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Boston Naming Test  | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| University of Pennsylvania Smell Identification Test-Brief | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| NIH Toolbox Flanker Test | T1, T2 |  | T1, T2 |  | T1, T2 |  | T1, T2 |  |
| Neurobehavioral Screen | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Perceived Stress Scale | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Snaith-Hamilton Pleasure Scale (Anhedonia) | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Toronto Alexithymia Scale | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| FrSBe Apathy | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| FrSBe Disinhibition | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| NIH Toolbox Fear/Anxiety | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| NIH Toolbox General Life Satisfaction | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| NIH Toolbox Loneliness | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| NIH Toolbox Instrumental Support | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| bWHODAS 2.0 | T2 | T1 |  |  |  |  |  |  |
| bDSM-5-TR Cross Cutting Symptom Measure | T2 | T1 |  |  |  |  |  |  |
| Alcohol Use Disorders and Associated Disabilities Interview Schedule-5 (AUDADIS-5)  | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Pittsburgh Sleep Quality Index- PSQI | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Beck Depression Inventory-II | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| bGAD-7  | T2 | T1 |  |  |  |  |  |  |
| bPHQ-9  | T2 | T1 |  |  |  |  |  |  |
| Kreek–McHugh–Schluger–Kellogg Scale (KMSK) | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 |
| Neuroimaging | MRI (optional) |  |  |  |  |  |  |  |  |
|  |  T1w  | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  T2w  | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  FLAIR  | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  Resting State fMRI  | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  PC Arterial Spin Labeling  | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  MRS frontal gray | T1, T2 |  |  |  | T1, T2 |  |  |  |
|  MRS frontal white | T1, T2 |  |  |  | T1, T2 |  |  |  |

Notes:

Data collection continues beyond Year 4, with a repeating schedule of assessments

T1= Tier 1 (Medically/socially unstable, require close follow up)

T2 = Tier 2 (Average acuity for organ donation study)

†Obtained only from individuals living with HIV (PWH)

‡Obtained only from individuals without HIV infection (PWoH)

\*May be abstracted/supplemented by a review of medical or pharmacy records

aNew measure that is administered only once at baseline to newly enrolled participants

bNew measure that is administered only once at baseline to new participants, or at the next onsite visit to existing participants